1. Home
  2. ITGR vs LQDA Comparison

ITGR vs LQDA Comparison

Compare ITGR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integer Holdings Corporation

ITGR

Integer Holdings Corporation

HOLD

Current Price

$85.36

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$39.04

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITGR
LQDA
Founded
1970
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.1B
IPO Year
2000
2018

Fundamental Metrics

Financial Performance
Metric
ITGR
LQDA
Price
$85.36
$39.04
Analyst Decision
Buy
Strong Buy
Analyst Count
7
10
Target Price
$86.67
$38.60
AVG Volume (30 Days)
707.1K
1.9M
Earning Date
02-19-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.42
N/A
Revenue
$1,831,074,000.00
$69,216,000.00
Revenue This Year
$9.58
$993.31
Revenue Next Year
N/A
$219.14
P/E Ratio
$35.95
N/A
Revenue Growth
9.54
343.41
52 Week Low
$62.00
$11.26
52 Week High
$144.76
$46.67

Technical Indicators

Market Signals
Indicator
ITGR
LQDA
Relative Strength Index (RSI) 52.40 47.22
Support Level $84.60 $38.88
Resistance Level $87.21 $46.67
Average True Range (ATR) 2.07 2.44
MACD -0.40 -0.72
Stochastic Oscillator 38.50 2.70

Price Performance

Historical Comparison
ITGR
LQDA

About ITGR Integer Holdings Corporation

Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: